Modality
Small Molecule
MOA
EZH2i
Target
TIM-3
Pathway
mTOR
Meso
Development Pipeline
Preclinical
~Oct 2016
→ ~Jan 2018
Phase 1
~Apr 2018
→ ~Jul 2019
Phase 2
~Oct 2019
→ ~Jan 2021
Phase 3
~Apr 2021
→ ~Jul 2022
NDA/BLA
Oct 2022
→ Oct 2029
NDA/BLACurrent
NCT07725954
285 pts·Meso
2022-10→2029-10·Terminated
285 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (1)
2029-10-073.5y awayPh3 Readout· Meso
Trial Timeline
Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q4
NDA/BLA
Termina…
Catalysts
Ph3 Readout
2029-10-07 · 3.5y away
Meso
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07725954 | NDA/BLA | Meso | Terminated | 285 | CfB |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Adagrazumab | Novartis | Phase 2/3 | Cl18.2 | |
| Ribotuximab | Merck & Co | Phase 2 | GPRC5D | |
| NVO-9615 | Novo Nordisk | Phase 2/3 | PRMT5 | |
| REG-6699 | Regeneron | Phase 2/3 | TIM-3 | |
| Nidasacituzumab | United Therapeutics | Phase 1/2 | TIM-3 | |
| Polalucimab | Jazz Pharma | Preclinical | PLK4 | |
| ASN-7038 | Ascendis Pharma | Phase 3 | VEGF | |
| Doxazasiran | Axsome | Phase 1 | TIM-3 | |
| Rimanesiran | Merus | Phase 1 | TIM-3 | |
| Tezetapinarof | CG Oncology | Phase 3 | VEGF |